Page last updated: 2024-12-09

1-[[(5-hex-1-ynyl-2-furanyl)-oxomethyl]amino]-3-phenylurea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You're asking about a very specific compound, **1-[[(5-hex-1-ynyl-2-furanyl)-oxomethyl]amino]-3-phenylurea**. While I can't give you a definitive answer about its specific importance in research, I can provide you with some insights based on its chemical structure and potential applications.

**Understanding the Structure:**

* **Phenylurea:** This is a core structure that is frequently found in herbicides and fungicides. It's known to have biological activity.
* **Furanyl:** The furan ring is a five-membered heterocyclic ring containing oxygen. It's often found in natural products and pharmaceuticals.
* **Hex-1-ynyl:** This is a six-carbon chain with a triple bond at the first carbon. This feature can contribute to lipophilicity (fat solubility) which can be important for drug uptake.
* **Oxomethyl:** This indicates a carbonyl group (C=O) attached to the furan ring.

**Possible Research Applications:**

Given the chemical structure, this compound could potentially be investigated for:

* **Herbicidal activity:** The phenylurea core and the overall structure suggest a potential for interaction with plant growth pathways.
* **Fungicidal activity:** Phenylureas are known to exhibit fungicidal properties.
* **Pharmaceutical activity:** The furan ring and the presence of a carbonyl group could lead to interactions with biological targets in the body.
* **Material science:** The combination of a rigid furan ring and a flexible alkyne chain could lead to interesting properties for material synthesis.

**How to Find More Information:**

1. **Search databases:** Use databases like PubChem, SciFinder, and Reaxys to see if the compound has been previously synthesized and characterized. You might find experimental data and potential applications mentioned.
2. **Academic search engines:** Search for research papers using the compound's name or related keywords (e.g., phenylurea herbicides, furan derivatives, alkyne synthesis).

**Important Note:** I am an AI language model and cannot provide specific experimental data or confirm the importance of this compound. It's crucial to consult scientific databases and literature to get accurate information on the topic.

Cross-References

ID SourceID
PubMed CID600239
CHEMBL ID1422017
CHEBI ID112726

Synonyms (12)

Synonym
smr000459632
MLS000860848
n1-phenyl-2-{[5-(1-hexynyl)-2-furyl]carbonyl}-1-hydrazinecarboxamide
CHEBI:112726
1-[(5-hex-1-ynylfuran-2-carbonyl)amino]-3-phenylurea
HMS2800N24
semicarbazide, 4-[5-(1-hexynyl)-2-furoyl]-1-phenyl-
VZMYQQFTTDQZAS-UHFFFAOYSA-N
2-[5-(1-hexynyl)-2-furoyl]-n-phenylhydrazinecarboxamide #
CHEMBL1422017
1-[[(5-hex-1-ynyl-2-furanyl)-oxomethyl]amino]-3-phenylurea
Q27192841
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
ureas
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency56.23410.631035.7641100.0000AID504339
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency36.42610.125919.1169125.8920AID2549; AID504841
Chain A, Ferritin light chainEquus caballus (horse)Potency39.81075.623417.292931.6228AID485281
glp-1 receptor, partialHomo sapiens (human)Potency31.62280.01846.806014.1254AID624417
GLS proteinHomo sapiens (human)Potency28.18380.35487.935539.8107AID624170
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency2.81840.707912.194339.8107AID720542
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency1.58490.354828.065989.1251AID504847
DNA polymerase betaHomo sapiens (human)Potency22.38720.022421.010289.1251AID485314
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency10.00000.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's5 (62.50)24.3611
2020's2 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.17 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]